Showing results (1-10 of 6) with videos related to
Sort By:
Pageof 1
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2013
Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotateEsther I van Vliet, Eric P Krenning, Jaap J Teunissen, et al.European Journal of Nuclear Medicine and Molecular Imaging|December 4, 2015
Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CTTheodosia Maina, Hendrik Bergsma, Harshad R Kulkarni, et al.Best Practice & Research. Clinical Gastroenterology|April 16, 2013
Peptide receptor radionuclide therapy (PRRT) for GEP-NETsHendrik Bergsma, Esther I van Vliet, Jaap J M Teunissen, et al.European Journal of Nuclear Medicine and Molecular Imaging|May 11, 2016
Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotateHendrik Bergsma, Mark W Konijnenberg, Wouter A van der Zwan, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 5, 2017
Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine TumorsHendrik Bergsma, Kirsten van Lom, Marc H G P Raaijmakers, et al.European Journal of Nuclear Medicine and Molecular Imaging|October 1, 2015
Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and courseHendrik Bergsma, Mark W Konijnenberg, Boen L R Kam, et al.Pageof 1